Triple

T11074746
Position Surface form Disambiguated ID Type / Status
Subject CLEOPATRA trial E261834 entity
Predicate fullName P16 FINISHED
Object CLinical Evaluation Of Pertuzumab And TRAstuzumab
CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) is a landmark phase III clinical trial that evaluated the addition of pertuzumab to trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.
 E902898 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: CLinical Evaluation Of Pertuzumab And TRAstuzumab | Statement: [CLEOPATRA trial, fullName, CLinical Evaluation Of Pertuzumab And TRAstuzumab]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: CLinical Evaluation Of Pertuzumab And TRAstuzumab
Context triple: [CLEOPATRA trial, fullName, CLinical Evaluation Of Pertuzumab And TRAstuzumab]
  • A. pertuzumab
    Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
  • B. HER2 receptor
    The HER2 receptor is a cell surface protein and member of the epidermal growth factor receptor family that, when overexpressed, drives the growth of certain aggressive breast and other cancers.
  • C. Herceptin
    Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
  • D. ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
    ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
  • E. Ibrance
    Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: CLinical Evaluation Of Pertuzumab And TRAstuzumab
Triple: [CLEOPATRA trial, fullName, CLinical Evaluation Of Pertuzumab And TRAstuzumab]
Generated description
CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) is a landmark phase III clinical trial that evaluated the addition of pertuzumab to trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: CLinical Evaluation Of Pertuzumab And TRAstuzumab
Target entity description: CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) is a landmark phase III clinical trial that evaluated the addition of pertuzumab to trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.
  • A. pertuzumab
    Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
  • B. HER2 receptor
    The HER2 receptor is a cell surface protein and member of the epidermal growth factor receptor family that, when overexpressed, drives the growth of certain aggressive breast and other cancers.
  • C. Herceptin
    Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
  • D. ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
    ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
  • E. Ibrance
    Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d6aa9983c08190b0ef61603b69feac completed April 8, 2026, 7:20 p.m.
NER Named-entity recognition batch_69d7994efb608190a81bc8c4d16ddbd0 completed April 9, 2026, 12:19 p.m.
NED1 Entity disambiguation (via context triple) batch_69e3c8cc77988190aad54f56dbd0f8cf completed April 18, 2026, 6:09 p.m.
NEDg Description generation batch_69e3cefc00148190a1850dc6e31523c3 completed April 18, 2026, 6:35 p.m.
NED2 Entity disambiguation (via description) batch_69e3d014a644819092c76aa02b573ca9 completed April 18, 2026, 6:40 p.m.
Created at: April 8, 2026, 9:26 p.m.